|
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Of all gliomas, 59% demonstrated aberrant copy numbers of BMI1.
|
18427816 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
HOX expression patterns identify a common signature for favorable AML.
|
18668134 |
2008 |
|
Myeloid Leukemia, Chronic
|
0.100 |
Biomarker
|
disease |
LHGDN |
Using qRT-PCR, we demonstrated a significantly increased level of Bmi-1 transcript in CML cells.
|
17454639 |
2007 |
|
Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Together with the rapid induction of Bmi1 expression on addition of Shh or on overexpression of the Shh target Gli1 in cerebellar granule cell cultures, these findings implicate BMI1 overexpression as an alternative or additive mechanism in the pathogenesis of medulloblastomas, and highlight a role for Bmi1-containing polycomb complexes in proliferation of cerebellar precursor cells.
|
15029199 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Further, primary melanoma lacking lymphatic metastases at presentation (pN0, n = 40) was less frequently BMI-1 positive than melanomas presenting with lymphatic metastases (pN1; n = 24; 52% versus 83%; p = 0.01).
|
17597110 |
2007 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
BMI1 was preferentially expressed in SP cells in Huh7 and PLC/PRF/5 HCC cells compared with the corresponding non-SP cells.
|
18829528 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The expression of Bmi1 and EZH2 was heterogeneous and associated with vascular infiltration, the histological grades, and the cell proliferation activity in HCC and HC-CC.
|
18591938 |
2008 |
|
Neuroblastoma
|
0.090 |
Biomarker
|
disease |
LHGDN |
Thus, Bmi-1 acts in a concentration-dependent manner in the control of the delicate balance between the self-renewal and differentiation of neuroblastoma I-type cells.
|
16982619 |
2006 |
|
Mammary Neoplasms
|
0.080 |
Biomarker
|
group |
LHGDN |
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients.
|
17711569 |
2007 |
|
Mammary Neoplasms
|
0.080 |
AlteredExpression
|
group |
LHGDN |
Here, we report that the expression of Bmi-1 and Mel-18 inversely correlates in a number of breast cancer cell lines and in a significant number of breast tumor samples.
|
17545584 |
2007 |
|
Mammary Neoplasms
|
0.080 |
AlteredExpression
|
group |
LHGDN |
Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients.
|
18228133 |
2009 |
|
Bladder Neoplasm
|
0.070 |
AlteredExpression
|
disease |
LHGDN |
We aimed to evaluate expression of BMI1 gene in bladder tumors.
|
18592462 |
2008 |
|
Hodgkin Disease
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
Analysis of HOXB9 regulation in HL cells revealed E2F3A and BMI1 as activator and repressor, respectively.
|
17148583 |
2007 |
|
Hodgkin Disease
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
We show here that Bmi-1 and LMP1 down-regulate the ataxia telangiectasia-mutated (ATM) tumor suppressor and conclude that Bmi-1 contributes to LMP1-induced oncogenesis in HL.
|
17148591 |
2007 |
|
Prostatic Neoplasms
|
0.030 |
Biomarker
|
group |
LHGDN |
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
|
17134822 |
2007 |
|
Prostatic Neoplasms
|
0.030 |
Biomarker
|
group |
LHGDN |
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
|
16963837 |
2006 |
|
Lymphoid leukemia
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
These results link E2a-Pbx1 with Bmi-1 on an oncogenic pathway that is likely to play a role in the pathogenesis of human lymphoid leukemias through downregulation of the INK4A-ARF gene.
|
14536079 |
2003 |
|
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.
|
18264721 |
2008 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes.
|
16107895 |
2005 |
|
Blast Phase
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
In a cohort of 64 CML patients, the level of BMI1 at diagnosis correlated with time to transformation to blast crisis, and the combination of low BMI1 and high proteinase-3 expression was associated in multivariate analysis with an improved overall survival (P = .001).
|
17360938 |
2007 |
|
Carcinoma, Papillary
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Furthermore, despite their different biologies, BMI-1 was strongly expressed in both papillary carcinomas and oncocytomas.
|
18347933 |
2008 |
|
Endometrial Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.
|
18475299 |
2008 |
|
Biliary cirrhosis
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Decreased expression of Bmi1 is closely associated with cellular senescence in small bile ducts in primary biliary cirrhosis.
|
16936260 |
2006 |
|
Mouth Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival.
|
17179983 |
2007 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
LHGDN |
BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.
|
18701473 |
2008 |